WebMD, QualityHealth.com merger terminated

Share this article:

A merger between WebMD and Marketing Technology Solutions (MTS) – the parent of QualityHealth.com – has been terminated.

The $50 million merger, announced in mid-September, had been expected to be finalized by Oct. 15. Instead, WebMD has “acquired a minority preferred interest in MTS,” the statement said. Financial terms were not disclosed. A spokesperson for WebMD declined to comment on the details of the failed merger.

WebMD also entered into an advertising services agreement with QualityHealth.com, allowing WebMD to represent a portion of QualityHealth.com's media inventory. Conversely, QualityHealth.com will have limited access to certain parts of WebMD's inventory, according to the spokesperson. QualityHealth.com was not immediately available for comment.

Following a merger with Revolution Health, Waterfront Media's Everyday Health Network topped WebMD in terms of unique visitors for October, according to comScore data. WebMD had previously led the category for nearly 10 years. QualityHealth.com ranked eighth in unique visitors for October, at 7.3 million. Had the WebMD, QualtyHealth.com merger gone through, WebMD would have been in a position to rival Everyday Health's unique visitor count, and possibly exceed it.

The WebMD Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList and theHeart.org.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...